CLDX Q1 2019 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-65.0% YoY

Gross Profit

-$10M-682.5% margin

Operating Income

-$18M-1259.0% margin

Net Income

-$17M-1209.8% margin

EPS (Diluted)

$-1.40

QoQ Revenue Growth

-19.2%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$148M

Total Liabilities

$35M

Stockholders' Equity

$113M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$4M	-65.0%
Gross Profit	-$10M	-$18M	+45.4%
Operating Income	-$18M	-$120M	+85.0%
Net Income	-$17M	-$118M	+85.4%

Revenue Segments

Grant

$1M91%

Service

$129,0009%